Atossa Therapeutics (ATOS) Capital Expenditures (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Capital Expenditures of -$711000.0 for Q1 2026, down 8000.0% year-over-year from $9000.0 in Q1 2025, and down 10257.14% quarter-over-quarter from $7000.0 in Q4 2025.
Atossa Therapeutics (ATOS) Capital Expenditures (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Capital Expenditures for 14 consecutive years, with -$711000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 8000.0% year-over-year to -$711000.0; the TTM figure through Mar 2026 stood at -$697000.0 (down 2589.29% YoY), while the FY2025 annual figure was $23000.0, up 21.05% from the prior year.
- Capital Expenditures retreated to -$711000.0 in Q1 2026 per ATOS's latest filing, from $7000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.7 million in Q3 2023 and bottomed at -$1.7 million in Q4 2023.
- Historically, Capital Expenditures has averaged -$48307.7 across 5 years, with a median of $7000.0 in 2025.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 6388.89% — and 2026, when it slumped 8000.0%.
- Atossa Therapeutics' Capital Expenditures stood at -$570000.0 in 2022, then tumbled by 195.26% to -$1.7 million in 2023, then surged by 98.75% to -$21000.0 in 2024, then soared by 133.33% to $7000.0 in 2025, then plunged by 10257.14% to -$711000.0 in 2026.
- Business Quant data shows ATOS's Capital Expenditures at -$711000.0 in Q1 2026, $7000.0 in Q4 2025, and $6000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 251.02 Mn |
| 10 | Atossa Therapeutics | 23.07 Mn | 23.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -711,000.00 |
| Mar 31, 2026 | -711,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 9,000.00 |
| Mar 31, 2025 | 9,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Dec 31, 2023 | -1.68 Mn |
| Dec 31, 2023 | -1.68 Mn |
| Sep 30, 2023 | 1.70 Mn |
| Sep 30, 2023 | 1.70 Mn |